Tofacitinib Versus Methotrexate in Treating Mucocutaneous and Musculoskeletal Lesions of Systemic Lupus Erythematosus: Real‐World Results From the <scp>CSTAR</scp> Cohort XXXII
Tofacitinib may demonstrate superior effectiveness over methotrexate in the resolution of mucocutaneous involvement in SLE patients, primarily by achieving remission more rapidly, while maintaining a comparable safety profile.
Authors
- Xinwang Duan (ORCID: https://orcid.org/0000-0002-0432-3638)
- Yunzhuan Chen
- Xinping Tian (ORCID: https://orcid.org/0000-0002-1511-7952)
- Qian Wang (ORCID: https://orcid.org/0000-0002-9674-4914)
- Yuehong Huo
- Leyao Ma (ORCID: https://orcid.org/0009-0003-4512-0700)
- Zhao Man (ORCID: https://orcid.org/0009-0003-2250-4090)
- Shengyun Liu (ORCID: https://orcid.org/0000-0003-3197-3158)
- Cheng Zhao (ORCID: https://orcid.org/0000-0002-7055-598X)
Institutions
- Ministry of Education of the People's Republic of China (CN)
- Nanchang University (CN)
- Guangxi Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Zhengzhou University (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- First Affiliated Hospital of GuangXi Medical University (CN)
- Zhengzhou People's Hospital (CN)
Publication Details
- Journal
- International Journal of Rheumatic Diseases
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1111/1756-185x.70283
- Citations
- 2
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 3.34
Funders
- Beijing Municipal Science and Technology Commission